Trials / Unknown
UnknownNCT02333513
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Hebei Yanda Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.
Detailed description
This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation. And, this trial is approved by medical ethics committee of hebei yanda hospital. Also, the trial has got a registry code "ChiCTR-OOC-15005759" in China clinical trial registry. Researchers will conduct thsi trial from 2015/02 to 2017/12, and 100 recurrent high-grade glioma with IDH1/2 mutation patients will be recruited. Patients who are recruited will get PCV chemotherapy in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lomustine/Vincristine/Procarbazine |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-01-07
- Last updated
- 2015-04-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02333513. Inclusion in this directory is not an endorsement.